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M ore than 36 million adults, about 15% of adults aged 18 years and older, reported being current cigarette users in 2015, de-spite it being the leading cause 
of preventable death in the United States (Jamal et 
al., 2016). Although the latest rate of smoking adults 
(15%) has decreased from 21% in 2008, the Healthy 
People 2020 target of 12% has yet to be reached (Of-
fice of Disease Prevention and Health Promotion, 
2017). Current smoking rates in the United States 
are higher among men, people aged younger than 65 
years, non-Hispanic American Indians/Alaska Natives 
or people of multiracial ethnicities, people with a high 
school degree or less, people living below the poverty 
level, and people with a disability or limitation (Cen-
ters for Disease Control and Prevention [CDC], 2017). 
Tobacco use is a known risk factor for many types 
of cancer, including the following: acute myeloid leu-
kemia, bladder cancer, cervical cancer, colon/rectal 
cancer, esophageal cancer, gastric cancer, laryngeal 
cancer, liver cancer, lung cancer, oral cancer, pan-
creatic cancer, pharyngeal cancer, renal cancer, and 
tracheal cancer. However, some cancer survivors con-
tinue to smoke cigarettes. The current smoking rate 
among cancer survivors is about 18%–27% (Harding, 
2012; Mayer & Carlson, 2011; Sterba et al., 2017; Tseng, 
Lin, Martin, Chen, & Partridge, 2010; Underwood et 
al., 2012; Wang, McLoone, & Morrison, 2015). Smoking 
cessation is vital to the survival and quality of life of 
this population, because continued smoking can lead 
to development of potential treatment interactions, 
secondary cancers, or exacerbation of comorbid con-
ditions, and it can have negative effects on quality of 
life (Armenian et al., 2016; Brown et al., 2003; CDC, 
2017; Leach et al., 2015; Wang et al., 2015). Survivors 
who continue to smoke have a significantly lower 
overall survival rate compared to those with the same 
cancers who do not smoke, and outcomes, includ-
ing total symptom burden, treatment toxicities, and 
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postoperative complications, are unfavorable in survi-
vors undergoing radiation, chemotherapy, and surgical 
treatments (Clark et al., 2007; Duffy et al., 2013; Fortin, 
Wang, & Vigneault, 2009; Peppone et al., 2011; Szeszko 
et al., 2015). In addition, continued smoking can 
worsen the late and long-term sequelae of cancer 
treatment, which commonly include hypertension 
and cardiac disease (Leach et al., 2015). This is import-
ant because cancer increases the risk of subsequent 
cardiovascular disease, which is the leading cause of 
death in cancer survivors when examining all-cause 
mortality (Armenian et al., 2016; Brown et al., 2003). 
Cancer survivors require care from a more support-
ive standpoint. Cancer can be a life-altering diagnosis 
for not only the patient, but also for family and friends 
(National Cancer Institute [NCI], 2017). For these 
patients, behavior modifications and healthy lifestyle 
choices are necessary to improve health, quality of life, 
and treatment outcomes. One barrier to smoking ces-
sation for this population is that current standards of 
tobacco cessation are not specific for cancer survivors 
and have not demonstrated the same efficacy compared 
to the general adult population (Toll, Brandon, Gritz, 
Warren, & Herbst, 2013). Evidence-based tobacco ces-
sation models and interventions involve assessments 
and treatments that lack evidence in studies specific to 
the oncology population (Toll et al., 2013). In addition, 
cessation rates among cancer survivors vary—not 
all patients are equally motivated to stop smoking—
and cessation often requires multiple multimodal 
approaches (NCI, 2017). The purpose of this article 
is to examine the prevalence of cigarette smoking in 
and characteristics of survivors after a cancer diagno-
sis. Identifying survivors at risk for continued smoking 
is important, because, as a clinician providing quality 
cancer, failure to address their tobacco addiction and 
smoking cessation care is unjustified and could be 
considered negligent (Patsakham, Ripley-Moffitt, & 
Goldstein, 2009). Current management strategies also 
will be presented.
Literature search terms included cancer, survi-
vorship, behavior, smoking, and quitlines. Databases 
searched were PubMed and CINAHL®. Databases were 
searched from the start of the database to December 
2016. Statistics, guidelines, and background informa-
tion were obtained from national websites, such as the 
American Cancer Society, NCI, National Institutes of 
Health, and CDC. Data evaluation included a manual 
search of PubMed and CINAHL, which led to 17 rel-
evant articles (see Table 1). Twelve articles were 
analyzed to identify variables among cancer survi-
vors who continue to smoke versus cancer survivors 
who successfully quit smoking after a diagnosis. Five 
articles were analyzed to identify characteristics of 
successful smoking cessation interventions among 
cancer survivors.
Variables in Continued Smoking 
for Cancer Survivors
Despite the known negative effects, 18%–27% of cancer 
survivors continue to smoke after a diagnosis (Harding, 
2012; Mayer & Carlson, 2011; Sterba et al., 2017; Tseng 
et al., 2010; Underwood et al., 2012; Wang et al., 2015). 
Rates of smoking continuation vary according to age, 
sex, race, marital status, type of cancer, socioeconomic 
status, and psychosocial factors. 
Gender
Higher rates of continued smoking are seen among 
female survivors. Multiple studies have identified 
higher smoking rates in women than men, as well as 
significantly greater odds of being a current smoker, 
versus a former smoker, in female survivors (adjusted 
odds ratio [AOR] = 1.4) (Burcu, Steinberger, & Sorkin, 
2016; Kim, Kim, Park, Shin, & Song, 2015; Tseng et al., 
2010; Underwood et al., 2012). Smoking prevalence, 
including rates of continued smoking after a diagno-
sis, were higher among female survivors (22%, 42%) 
compared to male survivors (13%, 28%), and women 
had a six-times higher risk of continued smoking after 
a diagnosis (Burcu et al., 2016; Kim et al., 2015; Tseng 
et al., 2010; Underwood et al., 2012). Associated vari-
ables, including cervical cancer, were linked to gender 
in many of the studies reviewed. Cervical cancer 
can be successfully diagnosed and treated in many 
women, and, like cigarette smoking, it is most preva-
lent in young, poor, and underserved women (Singh, 
Miller, Hankey, & Edwards, 2004).
Age
Younger patients are more likely to continue smoking 
after a diagnosis. Specifically, patients aged 40 years 
or younger had the highest rates of continued smok-
ing (45%–46%) (Burcu et al., 2016; Harding, 2012; Kim 
et al., 2015; Shoemaker, White, Hawkins, & Hayes, 
2016; Tseng et al., 2010). Compared to cancer survi-
vors aged older than 40 years, survivors aged 18–40 
years had significantly (p < 0.001) higher rates of 
continuing smoking after diagnosis (Harding, 2012; 
Shoemaker et al., 2016). 
Race
Continued smoking rates vary among racial groups. 
In a cross-sectional study among tobacco-related 
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smokers and 85 
were not current 
smokers
76% of current smokers identified as White. Current smoking 
rates were significantly higher in survivors not married or not 
living with their partner (59%, p = 0.004). Current smokers 
were less likely to be married (p = 0.04) and had lower per-
ceived social support from their partner (p = 0.04). Survivors 
with a household income less than $2,399 per month had a 
current smoking rate of 67%. Current smoking rate was 72% 
among survivors who were not employed. 23% of survivors 
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139 total 
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smokers and 85 
were not current 
smokers
After controlling for age, gender, ethnicity, marital status, and 
household income, significant factors associated with con-
tinued smoking were a diagnosis with other smoking-related 
cancers versus lung or head and neck cancer (OR = 11.21, 
95% CI [2.85, 44.02], p = 0.001) and screening positive 
for significant symptoms of depression (OR = 1.25, 95% CI 
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Prevalence of current smoking was higher among survivors 
without health insurance (41%) compared to those with it 
(20%). Survivors without insurance had twofold greater odds 
of not quitting. Those with insurance experiencing problems 
with access to care had 60%–80% greater odds of not quit-
ting. Those with insurance had lower cessation rates if they 












at 3 and 6 months
Prospective, longi-
tudinal study
132 participants at 
3 months and 121 
at 6 months
The abstinence rate was 68% (lung cancer, 65%; head and 
neck cancer, 72%) at 3 months and 61% (lung cancer, 53%; 
head and neck cancer, 68%) at 6 months. The continuous 
abstinence rate was 71% (lung cancer, 71%; head and neck 
cancer, 70%) at 3 months and 52% (lung cancer, 40%; head 
and neck cancer, 64%) at 6 months. Lower cancer-related, 
psychological, and nicotine withdrawal symptoms were asso-
ciated with increased abstinence rates. Decreased craving 
and increased self-efficacy were the most consistent factors 
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systematic review of 
smoking prevention 
and cessation inter-
ventions that have 








2,211 adult and 
childhood cancer 
survivors
Two interventions significantly increased smoking cessation 
rates among cancer survivors. Few interventions have been 
developed to improve smoking prevention and cessation rates 
in cancer survivors. Successful interventions included peer 
counseling, cognitive behavioral therapy exercises, and the 




To develop and test 
a tailored smoking, 
alcohol, and 
depression inter-
vention for patients 
with head and neck 
cancer
RCT measuring data 
collected, including 
smoking, alcohol 
use, and depressive 
symptoms at base-
line and 6 months
184 total enrolled 
(91 in the control 
group and 93 in the 
intervention group)
Significant differences in 6-month smoking cessation rates 
were noted, with 47% quitting in the intervention group 
compared to 31% in usual care (p < 0.05). The interven-
tion increased smoking cessation rates by 50% more than 
enhanced usual care. Treating comorbid depression and 
alcohol, both known to exacerbate smoking, may improve 
cessation rates.
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The quit rate was significantly higher in the counseling group 
compared with the self-help group at the 8-month (17% 
versus 9%; p < 0.01) and 12-month follow-up (15% versus 
9%; p ≤ 0.01). The Partnership for Health intervention 
resulted in a doubling of quit rates. With controlling for base-
line self-efficacy and readiness to change, the intervention 
group was twice as likely to quit. The smoking cessation rate 
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reported a previous 
cancer diagnosis
316 survivors (18%) indicated current smoking. The rate of 
current smoking was higher among younger cancer survivors 
aged 18–40 years (28%, 95% CI [23.1, 30.4]) compared 
to survivors aged 60–80 years (14%, 95% CI [11.5, 16.2]). 
Participants reporting smoking behaviors were significantly 
more likely to have reported feelings of anxiety, sadness, and 
hopelessness much more of the time compared to former or 
never smokers (p < 0.01). Survivors continued to smoke at a 
rate similar to the national average. Most respondents reported 
no symptoms of psychological distress. Age appeared to play a 
major role, showing significant differences in the prevalence of 
current smoking, participation in physical activity, alcohol use, 
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with head and neck 
cancer who were 
treated with curative 
intent
49% were current smokers at diagnosis, and 50% quit after 
diagnosis. Quitters were more likely to have smoked for fewer 
years (p = 0.0003), never used other forms of tobacco (p = 
0.0003), and consumed less alcohol (p = 0.002). No cigarette 
exposure at home (OR = 7.44, 95% CI [3.04, 18.2]), no 
spousal smoking (OR = 4.25, 95% CI [1.7, 10.6]), and having 
fewer friends who smoke (OR = 2.32, 95% CI [1, 5.37]) were 
consistent predictors of smoking cessation after diagnosis. 
Having none of these exposures and seeing a family physician 
were independently associated with smoking cessation. 68% 
of patients quit within 6 months of diagnosis. Patients who were 
ex-smokers at diagnosis were older, more likely to be female and 
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130 Korean men 
and women aged 
19 years or older 
who smoked at time 
of diagnosis (57 
smokers who quit 
and 73 persistent 
smokers)
Factors associated with persistent smoking after multivariable 
adjusted evaluation were female gender (OR = 5.99, 95% CI 
[1.38, 26.01], p = 0.018), low income (bottom 25%) (OR = 
3.24, 95% CI [1.22, 8.62], p = 0.019), high-risk alcohol use 
(OR = 3.79, 95% CI [1.43, 10.03], p = 0.008), body mass 
index greater than 25 kg/m2 (OR = 2.91, 95% CI [1.01, 8.34], 
p = 0.048), smoker in the household (OR = 8.39, 95% CI 
[1.95, 36.07], p = 0.005), and longer duration of smoking 
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cacy of two common 
types of tobacco 
quitlines in adult 
cancer survivors who 
regularly smoked
RCT, conducted over 
multiple facilities 




12-month self-reported abstinence was 22% and 26% for 
proactive and reactive groups. 48% of participants who were 
tested for cotinine failed biochemical verification, indicating 
a considerable falsification of self-reported cessation. Addi-
tional studies should include biochemical verification.
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cessation rates in 
patients with cancer
Systematic review of 
cessation interven-
tions at 5-week and 
6-month follow-up
1,301 adults aged 
older than 18 years 
with cancer who 
smoke
Interventions had a pooled OR of 1.54 (95% CI [0.909, 2.64]) 
in patients after 5 weeks and 1.31 (95% CI [0.931, 1.84]) 
after 6 months. Interventions in the perioperative period had 
a pooled OR of 2.31 (95% CI [1.32, 4.07]). Cessation inter-
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17% of survivors reported current smoking, with higher rates 
among women (p < 0.0001). Women aged 18–34 years were 
almost twice as likely to smoke as men of that age (p = 0.002). 
After exclusion of cervical cancer survivors, significant gender 
differences in current smoking rates were not evident. Of survi-
vors reporting smoking prior to diagnosis (24%), 11% quit within 
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ment of squamous 
cell carcinoma of the 
oral cavity, larynx, 
or pharynx. Patients 
were excluded if they 
were younger than 
21 years, were not 
surgical candidates, 
or had a cognitive 
impairment. 
Smoking status was significantly associated with cancer-specific 
symptoms (7 of 17 symptoms assessed). Current or recent 
smokers were less likely than former smokers to have ade-
quate finances (53% versus 89%, p = 0.001) and be married 
or partnered (55% versus 79%, p = 0.03). Current or recent 
smokers were more likely than former and never smokers to be 
unemployed (49% versus 40% and 13%; p = 0.02) and lack 
health insurance (17% versus 5% and 13%; p ≤ 0.04). Fatalistic 
beliefs (p = 0.03) and lower religiosity (p = 0.04) were more 
common in current or recent than never smokers. In models 
adjusted for sociodemographic and clinical factors, current or 
recent smokers reported more issues with swallowing, speech, 
and cough (p ≤ 0.04) and with social contact, feeling ill, and 
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cancer survivors, 
and compare demo-
graphic profiles of 
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vivors and 22,441 
individuals without 
cancer who were 
aged 20 years or 
older and partici-
pated in the 10-year 
National Health and 
Nutrition Examina-
tion Survey
18% of those reporting a cancer history continued to smoke. 
The smoking rate was higher in survivors aged younger than 40 
years (45%) than in young individuals without cancer (30%) 
(p = 0.001). Cervical cancer survivors had the highest current 
smoking rate (44%). Survivors of cervical cancer (23%) and 
melanoma (23%) had the lowest quit rate following diagnosis. 
Age, race, education, marital status, and time since diagnosis 
were important predictors of smoking status. Current smoking 
rates decreased with age in both populations. Survivors of 
cervical cancer, colon cancer, and melanoma had higher 
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adults aged 18 
years or older who 
could be contacted 
via telephone
Smoking prevalence was 27% among tobacco-related cancer 
survivors, 18% among respondents without cancer, and 16% 
among those with other cancers. The quit ratio was lowest 
among tobacco-related cancer survivors (55%). Prevalence was 
higher among women than men with cancer (31% versus 18% 
among tobacco-related cancer survivors and 12% versus 10% 
among those with other cancers). Prevalence decreased with age 
but increased with time since diagnosis in both survivor groups. 
Almost half of all multiracial and American Indian/Alaskan 
Natives were current smokers. Smoking prevalence was highest 
in cervical (33%), bladder (27%), lung (24%), and renal (23%) 
cancer. Smoking prevalence was significantly higher among 
tobacco-related cancer survivors compared to other survivors. 
Continued on the next page
cancer  survivors (lung, oral, pharynx, larynx, esoph-
agus, bladder, stomach, cervix, kidney, pancreas, 
acute myeloid leukemia), 41 (76%) current smokers 
identified as being White (Berg, Carpenter, Jardin, & 
Ostroff, 2013; Berg, Thomas, et al., 2013). Additional 
studies revealed mixed reviews; other races (exclud-
ing White, Black, and Hispanic descent) were more 
likely to continue smoking (24%) (Tseng et al., 2010), 
and smoking rates were comparable across racial 
groups of cancer survivors (Burcu et al., 2016). In a 
secondary data analysis using data from the 2009 
Behavioral Risk Factor Surveillance System, Alaskan 
Natives/American Indians and multiracial respon-
dents had the highest rates of smoking prevalence 
among cancer survivors (Underwood et al., 2012). In 
fact, about half of Alaskan Natives/American Indians 
(more than 50%) and multiracial (50%) participants 
identified as current smokers after a cancer-related 
diagnosis (Underwood et al., 2012). 
Marital Status
Cancer survivors who continue to smoke are less likely 
to be partnered. Rates of continued smoking were 
significantly higher in survivors who were unmar-
ried or not living with their partner (59%, p = 0.004). 
Specifically, current or recent smokers were less likely 
than former smokers to be partnered (p = 0.03); 30% 
of patients with cancer who continued to smoke were 
never married, and 25% were widowed, divorced, or 
separated (Berg, Carpenter, et al., 2013; Berg, Thomas, 
et al., 2013; Sterba et al., 2017; Tseng et al., 2010). In 
survivors who were partnered, those who had lower 
perceived social support from their significant other 
had significantly higher rates of continued smoking (p = 
0.04) (Berg, Carpenter, et al., 2013; Berg, Thomas, et al., 
2013). A significant dose effect occurred in the home, 
because smoking cessation was strongly and nega-
tively associated with larger amounts of time exposed 
to secondhand smoke, meaning longer exposure led to 
less cessation (p = 0.004) (Kashigar et al., 2013). Social 
environments, including if one’s spouse smoked and 
amount of time exposed to smoke in the home, were 
the most important socials factors associated with 
continued smoking in survivors (Kashigar et al., 2013). 
Socioeconomic Status
Socioeconomic status, including income, insurance, 
and employment, has been associated with continued 
smoking in cancer survivors. Survivors with a lower 
household income and a lower income-to-poverty ratio 
were found to have higher rates of continued smoking 
(Berg, Carpenter, et al., 2013; Berg, Thomas, et al., 2013; 
Burcu et al., 2016; Kim et al., 2015; Sterba et al., 2017; 
Tseng et al., 2010). In addition, smoking rates were 
higher among survivors who were not employed, were 
out of work, or were unemployed (Berg, Carpenter, et 
al., 2013; Burcu et al., 2016; Sterba et al., 2017). In addi-
tion, survivors with no reported health insurance had 
higher rates of continued smoking and were two times 
more likely to be current smokers (AOR = 2, 95% confi-
dence interval [CI] [1.2, 3.2]) (Burcu et al., 2016; Sterba 
et al., 2017; Underwood et al., 2012).
TABLE 1. Review of the Literature (Continued)








cal activity, smoking 
and alcohol con-
sumption) and 
obesity in survivors 
compared to those 
with no history of 
cancer and those 
who subsequently 
developed cancer
Case control study 16,282 adults aged 
older than 45 years 
who were diagnosed 
with cancer (n = 
922 diagnosed 
before survey; n = 
1,257 diagnosed 
after survey)
4,512 (28%) reported currently smoking. 197 (21%) with 
a previous diagnosis reported currently smoking. 447 
(36%) respondents who developed a subsequent cancer 
reported currently smoking. 147 (21%) current smokers were 
diagnosed before the survey with more than 2 years since 
diagnosis. 52 (23%) current smokers were diagnosed before 
the survey with less than 2 years since diagnosis. 80 (33%) 
current smokers were diagnosed after the survey with less 
than 2 years since diagnosis. 367 (36%) current smokers 
were diagnosed after the survey, with less than 2 years since 
diagnosis. Survivors were more likely to stop smoking com-
pared to those with no cancer history. Breast cancer survivors 
were most likely to quit. Current smoking was least prevalent 
among those within 2 years of diagnosis and higher in those 
diagnosed more than 2 years before.
CI—confidence interval; OR—odds ratio; RCT—randomized, controlled trial
Cancer Type
Cancer type is another variable associated with contin-
ued smoking; however, smoking rates vary across the 
studies reviewed. Among all those who smoked prior to 
diagnosis, 23% of cervical cancer survivors quit smok-
ing and 44% continued smoking after diagnosis (Tseng 
et al., 2010). Survivors of melanoma had similar pat-
terns: 23% of survivors quit smoking and 32% continued 
smoking after diagnosis (Tseng et al., 2010). In other 
studies, cancer survivors of smoking-related cancers, 
including cervical and lung, were found to have higher 
rates of continued smoking and lower abstinence rates; 
lung and head and neck cancer survivors had abstinence 
rates that decreased from three to six months (65% to 
53% for lung, 72% to 68% for head and neck) (Cooley et 
al., 2012). In addition, survivors of tobacco-related can-
cers had a significantly higher tobacco use rate (27%) 
compared to survivors of other cancers or those with 
no cancer at all (p < 0.001) (Underwood et al., 2012). 
Within this tobacco-related cancer survivor popula-
tion, women with cervical cancer reported a smoking 
prevalence of 35% (Underwood et al., 2012). 
Time Since Diagnosis
Smoking prevalence increases with time since diag-
nosis and duration of smoking. Smoking cessation 
interventions seemed to have a small effect size for sur-
vivors after two or more years after a diagnosis; a longer 
duration of smoking was positively associated with an 
increased risk of persistent smoking (odds ratio [OR] = 
1.12, 95% CI [1.02, 1.22], p = 0.015) (Kim et al., 2015; 
Wang et al., 2015). In addition, smoking prevalence 
among survivors increased to more than 20% follow-
ing 10 years or more after a diagnosis (Underwood et 
al., 2012). In the study by Cooley et al. (2012), smoking 
abstinence decreased with time for survivors of lung 
and head and neck cancers. The researchers discov-
ered that 71% of lung cancer survivors and 70% of head 
and neck cancer survivors remained abstinent at three 
months; however, cessation rates decreased in both 
groups after six months (40% for lung and 64% for 
head and neck cancer survivors) (Cooley et al., 2012). 
Psychosocial Factors
Psychosocial factors have been associated with con-
tinued smoking in cancer survivors. Continued 
smoking rates were higher in survivors who had a 
lower confidence of quitting, and only 23% of long-
term survivors reported attempting to quit within 
the past year (Berg, Carpenter, et al., 2013). In addi-
tion, continued smoking rates among survivors were 
significantly associated with fatalism (p = 0.03) and 
problems with social contact (p = 0.01) (Sterba et al., 
2017). Feelings of hopelessness, sadness, and anxi-
ety most of the time (p < 0.01), moderate to severe 
stress (p < 0.001), symptoms of depression (p < 
0.001), and lower reported physical and emotional 
well-being (p = 0.01) were significantly associated 
with continued smoking in multiple studies (Berg, 
Thomas, et al., 2013; Harding, 2012; Kim et al., 2015). 
Variables in Successful Smoking Cessation
Although some patients with cancer continue smok-
ing after a diagnosis, some survivors do successfully 
quit. Like continued smoking, smoking cessation 
rates vary by patient demographics, social support, 
socioeconomic status, cancer diagnosis, and psycho-
social factors. 
Patient Demographics
Sex, age, and ethnicity of survivors are associated with 
lower smoking rates and higher cessation rates. Most 
of the studies reviewed found that male survivors had 
higher cessation rates and were more likely to quit 
within one year of a diagnosis (Cooley et al., 2012; 
Harding, 2012; Tseng et al., 2010). Only one study 
found that women were significantly (p < 0.0001) more 
likely to be ex-smokers, compared to current smokers, 
at time of diagnosis; the investigators concluded that 
social smoking environments were stronger and more 
predictable factors for smoking cessation (Kashigar 
et al., 2013). Survivors aged 65 years or older had 
significantly lower smoking rates and significantly 
higher cessation rates in many of the studies reviewed 
(Harding, 2012; Kashigar et al., 2013; Shoemaker et 
al., 2016; Tseng et al., 2010; Underwood et al., 2012). 
Only one study identified race as a factor in smoking 
cessation and determined that 41% of White survivors 
quit smoking, compared to lower rates for Black survi-
vors (35%), Hispanic survivors (27%), and other races 
(24%) of survivors (Tseng et al., 2010). 
Social Support
Social support and nonsmoking environments are 
associated with higher cessation rates among cancer 
survivors. Survivors who were married or living with 
their partner had higher rates of smoking cessation 
(Berg, Carpenter, et al., 2013; Kashigar et al., 2013; 
Sterba et al., 2017; Tseng et al., 2010). Survivors rec-
ognized that cessation among loved ones and people 
close to them was helpful in maintaining a support-
ive and less tempting environment (Berg, Carpenter, 
et al., 2013). Specifically, having a spouse who did 
not smoke significantly increased the likelihood of 
quitting at diagnosis (p < 0.0001) or within one year of 
diagnosis (p ≤ 0.0005) (Kashigar et al., 2013). Positive 
social environments included no cigarette exposure 
in the home (AOR = 7.44, 95% CI [3.04, 18.2]), a non-
smoking spouse (AOR = 4.25, 95% CI [1.7, 10.6]), and 
fewer smoking peers (AOR = 2.32, 95% CI [1, 5.37]) 
(Kashigar et al., 2013). 
Socioeconomic Status
Socioeconomic status also affects rates of smoking ces-
sation among cancer survivors. Survivors who reported 
adequate monthly finances had higher rates of smok-
ing cessation (Berg, Carpenter, et al., 2013; Burcu et al., 
2016; Sterba et al., 2017; Tseng et al., 2010). Specifically, 
survivors with incomes greater than $50,000 per year 
or $2,399 per month were associated with higher rates 
of cessation (Berg, Carpenter, et al., 2013; Burcu et al., 
2016). A greater number of survivors who quit smoking 
were employed, had health insurance, and achieved an 
education level above high school (Burcu et al., 2016). 
Cancer survivors with a high school–level education or 
higher had significantly higher rates of cessation (p = 
0.02) (Kashigar et al., 2013). 
Cancer Diagnosis
Like smoking prevalence rates, smoking cessa-
tion rates vary among cancer type after a diagnosis. 
Some studies revealed that survivors of lung, larynx, 
tracheal, and other head and neck cancers had ces-
sation rates that were higher than those with other 
smoking-related cancers (Berg, Carpenter, et al., 2013; 
Berg, Thomas, et al., 2013; Kim et al., 2015; Tseng et al., 
2010). Continued smoking rates among patients with 
prostate (7%), colon (11%), and lung, larynx, and tra-
cheal (15%) cancers also were low compared to those 
with other cancers and had the highest quit-smoking 
rates after a diagnosis (prostate, 56%; colon, 52%; 
lung, larynx, and windpipe, 68%) (Tseng et al., 2010). 
Breast cancer survivors were more likely to be former 
smokers compared to lung, bowel, and prostate cancer 
survivors, and smoking was least prevalent in survi-
vors diagnosed within two years, because behavior 
changes occurred closer to a diagnosis (Wang et al., 
2015). Similarly, abstinence rates were higher at three 
months, compared to six months, after diagnosis 
among survivors of head and neck cancer (72% versus 
68%) who reported smoking prior to diagnosis (Cooley 
et al., 2012). Variations in abstinence rates across 
studies can be attributed to using data obtained via 
self-reported smoking status versus biochemical verifi-
cation, variations in definitions of abstinence, and time 
points of abstinence verification (Cooley et al., 2012). 
Psychosocial Factors
Finally, psychosocial factors, including intrapersonal 
issues and social support, influence smoking cessa-
tion rates. Greater self-efficacy (OR = 0.94, 95% CI 
[0.89, 1]) and less craving (OR = 0.52, 95% CI [0.31, 
0.88]) were significant factors associated with absti-
nence (Cooley et al., 2012). Survivors were more likely 
to remain abstinent if they reported lower levels of 
anxiety and depression, absence of withdrawal symp-
toms, and lower cancer-related distress (Cooley et 
al., 2012). In addition, survivors who quit smoking 
reported having fewer peers who smoked (78%, p < 
0.0001) and no exposure to smoke at home (84%, p < 
0.0001) (Kashigar et al., 2013).
Tobacco Cessation Interventions
The gold standard of tobacco cessation treatment 
remains the same for those with cancer as the gen-
eral population of adult and adolescent tobacco users 
(Karam-Hage, Cincirpini, & Gritz, 2014). To deliver 
effective interventions, clinicians must be familiar with 
and knowledgeable about tobacco cessation training. 
The U.S. Department of Health and Human Services 
(HHS) provides a guideline for tobacco treatment that 
can be adopted into practice for clinical use (Fiore et 
al., 2008). This guideline recommends a combination 
of advice and counseling, pharmacotherapy, follow-up, 
and assessment of difficulties (Fiore et al., 2008). 
5 A’s Model
The “5 A’s” model is used for treating tobacco use 
and dependence. This model can help clinicians ask 
patients about tobacco use, advise patients to attempt 
to quit, assess their readiness to quit, assist in quit 
attempts, and arrange for follow-up (Fiore et al., 
2008). At each clinic visit, clinicians should ask every 
patient about tobacco use and document the findings 
in the medical record (Fiore et al., 2008). For patients 
unmotivated to quit smoking, clinicians can use the 
“5 R’s” of motivational intervention to help persuade 
patients to make a change (University of Michigan 
Health System [UMHS], 2012). Clinicians should 
ask patients to identify the specific relevance, risks, 
rewards, roadblocks, and repetition of tobacco use 
in their life (UMHS, 2012). Clinicians should repeat 
these strategies at every clinic visit to assist unmoti-
vated patients with cessation (UMHS, 2012).
Pharmacologic Therapy
If clinicians decide to provide cessation therapy, 
pharmacologic therapy should be recommended to 
all patients who do not have any contraindication to 
the treatment (UMHS, 2012). The U.S. Food and Drug 
Administration (FDA) approved pharmacologic agents 
for nicotine replacement therapy (NRT), as well as 
bupropion hydrochloride sustained-release (Zyban®) 
and varenicline (Chantix®), which have shown to sig-
nificantly improve cessation rates (UMHS, 2012). In 
addition, cessation interventions should incorporate 
counseling along with pharmacologic treatments. 
Clinicians providing counseling should take a tai-
lored approach by assessing a patient’s barriers to 
tobacco cessation and motivation to quit (UMHS, 
2012). Clinicians should be aware of common barriers 
to quitting, such as severe withdrawal, lower socio-
economic status, stress, environment, psychiatric 
comorbidities, and multiple quit attempts (UMHS, 
2012). Knowing these barriers can better help cli-
nicians tailor counseling cessations by focusing on 
specific, individual problems that prevent patients 
from successful smoking cessation. 
Counseling
Clinicians can refer patients and encourage family 
members to receive counseling outside of the clini-
cal setting if not available within the setting. Intense, 
person-to-person counseling comprising weekly ses-
sions for the first four to seven weeks of treatment 
significantly enhances quit rates if the patient is 
motivated enough to quit (Fiore et al., 2008). These 
sessions often are held at local clinics, hospitals, or 
health departments. Tobacco treatment specialists, 
tobacco quit programs, tobacco quitlines, and coun-
seling websites can provide further information, 
advice, and reinforcement, particularly for patients 
of special populations (Fiore et al., 2008). The U.S. 
national quitline, 1-800-QUITNOW, is a resource 
that clinicians can use to provide convenient, 
telephone-based counseling to further deliver cessa-
tion support. In addition, patients who use quitlines 
have greater odds of long-term smoking cessation 
and significantly higher abstinence rates compared 
to those with no counseling (Kaufman, Augustson, 
Davis, & Rutten, 2010). Because tobacco use is a 
chronic disease, multiple relapses may occur before 
a patient can become fully abstinent, and these lapses 
can be used as a learning experience. 
Tobacco Cessation Interventions 
and Cancer Survivors
Few systematic reviews, meta-analyses, or ran-
domized, controlled trials (RCTs) have focused on 
cancer-specific tobacco cessation interventions, 
or the efficacy of standard treatments for cancer 
survivors. Current research is limited but suggests 
that smoking cessation interventions are less success-
ful among cancer survivors and that cancer survivors 
require a more tailored approach to smoking cessa-
tion (Abrams, 2016; de Moor, Elder, & Emmons, 2008; 
Karam-Hage et al., 2014; Klesges et al., 2015). 
In a systematic review on smoking cessation inter-
ventions in cancer survivors, de Moor et al. (2008) 
reviewed nine smoking cessation interventions for 
cancer survivors. The authors identified only two 
interventions that significantly increased smoking 
cessation rates. The first intervention, which was part 
of the Partnership for Health study, implemented 
peer counseling by childhood cancer survivors to 
current smokers who were childhood cancer survi-
vors (Emmons et al., 2005). The second intervention 
incorporated cognitive behavioral therapy (CBT) and 
pharmacotherapy for survivors with concurrent smok-
ing, alcohol use, and depression (Duffy et al., 2006). 
De Moor et al. (2008) concluded that higher-intensity 
interventions were more effective for cancer survivors. 
Specifically, longer contact and multiple sessions were 
associated with greater effectiveness for smoking ces-
sation (de Moor et al., 2008). The authors suggested 
that attention should be paid to risky health behaviors 
and comorbidities that may affect smoking status and 
smoking cessation, such as alcohol use and depression 
(de Moor et al., 2008). Interventions also should be 
designed around a theoretical framework and tailored 
to the survivors’ stage of readiness to quit smoking 
(de Moor et al., 2008). This could include motivat-
ing patients to quit during the precontemplation and 
contemplation phases of the transtheoretical model 
(Clark, Rakowski, Kviz, & Hogan, 1997). 
In a systematic review of smoking cessation 
interventions in cancer survivors, Nayan, Gupta, 
Strychowsky, and Sommer (2013) identified that 
tobacco cessation interventions in the oncology 
population, compared to other smokers, do not sig-
nificantly affect cessation rates. This review included 
10 RCTs and three prospective cohort studies (Nayan 
et al., 2013). Interventions were considered usual care 
and included behavioral therapy and pharmacother-
apy (Nayan et al., 2013). Specifically, interventions 
included CBT, self-help materials, education mod-
ules, motivational interviewing, NRT, bupropion, and 
varenicline (Nayan et al., 2013). The studies reviewed 
were single- or multicenter, and a total of 1,301 
patients were enrolled with no baseline differences 
in characteristics. In a subgroup analysis, Nayan et 
al. (2013) found that smoking cessation interventions 
provided during the perioperative period had a pooled 
OR of 2.31 (95% CI [1.32, 4.07]), which was the only 
significant finding of the review. The authors con-
cluded that, although no significant differences were 
found between cessation interventions and usual care 
in the oncology population, the perioperative period 
may provide an important teaching moment for 
smoking cessation (Nayan et al., 2013). 
Research suggests that older adults with health 
problems, family histories of cancer, and psycho-
logical distress are more likely to have ever called a 
quitline (Kaufman et al., 2010). Patients who use 
quitlines have a greater chance of long-term smoking 
cessation and significantly higher abstinence rates 
compared to those with no counseling (Kaufman 
et al., 2010). In the St. Jude Children’s Research 
Hospital Cancer Survivors tobacco quit line study, 
smoking abstinence rates were compared between a 
counselor-initiated quitline and a participant-initiated 
quitline among adult survivors of childhood cancer 
who smoke (Asfar et al., 2010). Social cognitive theory 
and social determination theory were used to formu-
late the intervention in the St. Jude study (Asfar et al., 
2010). This framework allowed participants in both 
intervention groups to practice short-term goal set-
ting, modify expectations of cessation, self-monitor, 
and practice self-reinforcement (Asfar et al., 2010). 
Study participants were randomly assigned to the 
intervention and control groups and received six 
telephone-based counseling sessions and as many as 
eight weeks of NRT (Asfar et al., 2010). Participants 
in the intervention group received telephone calls 
under counselor-directed therapy, and participants 
in the control group were directed to initiate all six 
telephone calls (Asfar et al., 2010). The telephone 
counseling sessions supported participants through 
three linear phases of quitting: preparing to quit, the 
quitting process, and relapse prevention and main-
taining abstinence (Asfar et al., 2010). 
Self-reported smoking status was reassessed eight 
weeks and one year postintervention, and biochemical 
verification via salivary cotinine testing was obtained 
for those who reported abstinence (Asfar et al., 2010). 
Of the 65 participants who reported successful smok-
ing cessation, 29 participants completed cotinine 
level testing (Asfar et al., 2010). In Klesges et al.’s 
(2015) study, 48% of participants reporting abstinence 
at one year failed biochemical verification, demon-
strating that they were still using tobacco products. 
In addition, tobacco cessation rates in both groups 
were less than 5%, with no significant differences 
between intervention groups (Klesges et al., 2015). The 
authors concluded that the findings of this study were 
consistent with previous research in that tobacco ces-
sation interventions result in nonsignificant outcomes 
within the adult oncology population (Klesges et al., 
2015). 
Discussion
Clinicians need to be aware of the growing popularity 
of electronic nicotine delivery systems (ENDS), includ-
ing electronic cigarettes. The number of adults using 
electronic cigarettes rose from 3% in 2010 to 14% in 
2015 (U.S. Department of Health and Human Services 
[USDHHS], 2016). Although electronic cigarettes are 
promoted as a less harmful alternative to traditional 
cigarettes, the long-term effects of these devices, as 
well as secondhand smoke from them, are unknown 
(USDHHS, 2016). In 2013, the FDA announced its 
concern about the health effects of ENDS, including 
concerns of worsening nicotine addictions among 
users, influencing users to try other tobacco products, 
and concerns about the known toxic substances used 
in these products (FDA, 2013). In addition, ENDS may 
prevent current smokers from using evidence-based 
cessation therapies (USDHHS, 2016). According 
to the Tobacco Control and Smoking Cessation 
Committee from the International Association for 
the Study of Lung Cancer, providers should encour-
age survivors who use electronic cigarettes to switch 
to an evidence-based cessation treatment (Cummings 
et al., 2014). Clinicians should be aware of this trend 
in tobacco use among survivors, should not recom-
mend electronic cigarettes as a cessation therapy, and 
should work to further explore and educate patients 
on the long-term and negative health effects of ENDS.
Implications for Nursing and Research
Despite the known negative effects of tobacco use, 
including potential treatment interactions, develop-
ment of secondary cancers, exacerbation of comorbid 
conditions, and negative impact on quality of life, a 
number of cancer survivors continue to smoke after a 
diagnosis (Karam-Hage et al., 2014; Wang et al., 2015). 
Some populations of cancer survivors are more at 
risk for continued smoking, and a lack of efficacy in 
tobacco cessation treatment can make smoking ces-
sation treatment difficult for clinicians and patients. 
Nurses and advanced practice providers should 
be aware of survivors who are at a higher risk for 
continued smoking. Survivors at risk are more likely 
to be aged younger than 40 years, female, and not 
partnered, and have less socioeconomic and psy-
chosocial support. These characteristics are similar 
to those of the general population of U.S. smokers. 
Because of findings of the secondary data analysis, 
Mayer and Carlson (2011) concluded that survivors 
have a greater likelihood of being a current smoker 
if they are younger, widowed or divorced, have little 
to no access to health care, and have less than a col-
lege education. In addition, smoking prevalence rates 
are higher among survivors of tobacco-related can-
cers, like cervical cancer, which can be successfully 
treated in many women, and, like cigarette smoking, 
is most prevalent in the young, poor, and underserved 
(Cooley et al., 2012; Mayer & Carlson, 2011; Tseng et 
al., 2010; Underwood et al., 2012). Although a cancer 
diagnosis related to smoking may provide highly 
addicted survivors motivation for cessation, it war-
rants more intensive cessation interventions from 
providers. With this information, nurses can better 
identify survivors at risk for continued smoking and 
educate survivors on the negative impacts of contin-
ued tobacco use. Smoking is a risk factor for a number 
of chronic health problems in adults, and nurses also 
can use this information to identify people who are at 
risk for smoking initiation. 
Clinicians can use the 5 A’s model for treating 
tobacco use and dependence to assess survivors’ cur-
rent tobacco use and readiness to quit and use this 
information to tailor necessary interventions. For 
example, Abrams (2016) suggested tailoring treatments 
for lung cancer survivors by extending counseling to 
people with whom a patient lives who also use tobacco. 
Social support and environment have been shown to 
play a significant role in smoking cessation (Kashigar 
et al., 2013; Sterba et al., 2017). In addition, clinicians 
can tailor interventions and help prevent relapse of 
tobacco use by prescribing antidepressant medications 
that also aid in smoking cessation, such as bupropion, 
for survivors with depression. At every office visit, 
survivors should be screened for tobacco use and 
depression because survivors are more likely to remain 
abstinent with lower levels of anxiety and depression, 
absence of withdrawal, and lower cancer-related dis-
tress (Cooley et al., 2012). Because smoking prevention 
is a key factor in health promotion, education in tai-
lored cessation methods, including the 5 A’s model and 
motivational interviewing techniques, can be provided 
in undergraduate nursing curricula. 
If providing smoking cessation interventions 
themselves, clinicians must be knowledgeable of the 
available pharmacotherapies and behavioral interven-
tions. To avoid drug–drug interactions, inactivation, 
and the exacerbation of side effects of cancer-related 
treatments, providers must be knowledgeable of the 
medications in smoking cessation treatment. For 
example, providers should be aware of the poten-
tial nausea with varenicline use before prescribing 
this medication to a patient receiving chemotherapy 
(Karam-Hage et al., 2014). Varenicline also requires 
dose adjustments for patients with altered kidney 
function and has been associated with cardiovascular 
events. Therefore, clinicians must be knowledgeable of 
a patient’s comorbid conditions and the long-term car-
diovascular and renovascular effects of chemotherapy 
to weigh the risks and benefits of select pharmacother-
apies. In addition, varenicline and bupropion can lower 
the seizure threshold and should be used with caution 
in patients treated with antidepressants and patients 
with a history of seizures, brain tumors, or metastases 
(UMHS, 2012). 
Clinicians also should realize that cancer survivors 
may require more intense and tailored counseling. 
Survivors should be followed closely over time with 
multiple contact sessions because abstinence rates 
can begin to decline with time. Counseling may be 
more effective in the perioperative period (de Moor 
et al., 2008; Nayan et al., 2013). 
The use of frameworks to guide interventions, 
such as the transtheoretical model and social 
cognitive/learning theory, can help patients focus on 
the importance of motivation to quit, barriers and ben-
efits to quitting, self-efficacy, and attitudes and cues to 
actions (de Moor et al., 2008; Roberts, Kerr, & Smith, 
2013). If unable to provide counseling services, clini-
cians should refer patients to a smoking behavioral 
specialist or counselor (Fiore et al., 2008). Although 
not demonstrating a significant change in long-term 
abstinence in the St. Jude study, quitlines, such as 
1-800-QUITNOW, can provide survivors with accessi-
ble and cost-effective telephone counseling (Fiore et
al., 2008; Klesges et al., 2015;  Sarna & Bialous, 2016).
In addition, quitlines can provide person-to-person
counseling that may not be available to survivors
facing barriers in access to care and increased risks of
continued smoking, such as unemployment, poverty,
and lack of insurance (Berg, Carpenter, et al., 2013;
KNOWLEDGE TRANSLATION
 ɐ Advanced practice providers should be aware of the variables that 
place survivors at risk for continued smoking. 
 ɐ Failure to identify these survivors and to address tobacco addic-
tion and smoking cessation in cancer care is unjustified.
 ɐ Survivors may require more intense, tailored smoking cessation 
treatments that incorporate unique cessation interventions. 
Berg, Thomas, et al., 2013; Burcu et al., 2016; Kim et 
al., 2015; Sarna & Bialous, 2016; Tseng et al., 2010). 
Individual clinician change is necessary for 
smoking cessation to occur among all patients with 
cancer. To support clinician change, systems-level 
changes are warranted. Such changes are identified 
in the HHS guideline and include implementing 
tobacco user identification systems; providing edu-
cation, feedback, and resources to promote provider 
interventions; using dedicated staff to provide and 
evaluate tobacco treatment and its delivery; imple-
menting hospital policies to support inpatient 
tobacco cessation services; and including coverage of 
tobacco cessation services (Fiore et al., 2008; Sarna 
& Bialous, 2016). Greater involvement of clinicians 
increases the chances of successful cessation; how-
ever, those providing cessation support must be 
knowledgeable about tobacco addiction and the evi-
dence-based strategies of cessation treatment (Sarna 
& Bialous, 2016; Sarna, Wewers, Brown, Lillington, 
& Brecht, 2001). This is particularly important to 
oncology nurses, who can reinforce cessation treat-
ments for unmotivated patients (Cooley, Sipples, 
Murphy, & Sarna, 2008). In addition, having a dedi-
cated tobacco cessation program can provide support 
to busy clinicians who may not have the time or train-
ing to implement and personalize evidence-based 
tobacco cessation treatments (Sarna & Bialous, 2016; 
Warren & Ward, 2015). In a cross-sectional study by 
Goldstein, Ripley-Moffitt, Pathman, and Patasakam 
(2013), components of cancer centers with and 
without tobacco use treatment (TUT) services were 
compared. The authors revealed that having a TUT 
program within cancer centers increased providers’ 
awareness of evidence-based tobacco support and 
treatments, ensured identification of all tobacco 
users, and provided more in-depth, individualized, 
and comprehensive treatment (Goldstein et al., 
2013). 
Finally, more research on cancer-specific tobacco 
cessation interventions is needed. According to the 
NCI (2017), few smoking intervention studies have 
been conducted in survivors because of survivors 
reporting nonsmoking status at diagnosis, medical 
histories or medications contraindicating smoking 
cessation interventions, noninterest in smoking ces-
sation, comorbid psychiatric conditions, and loss to 
follow-up from travel, death, and contact problems. 
Despite these issues, data on survivor populations at 
risk for continued smoking and interventions most 
effective in tobacco use cessation should be gathered 
and analyzed.
Conclusion
Cigarette smoking is the leading cause of preventable 
death in the United States, and health behavior mod-
ifications are essential to the prevention of cancer 
and other chronic disease (CDC, 2016, 2017). Using 
the HHS tobacco treatment guideline via the Agency 
for Healthcare Research and Quality website, provid-
ers can assist smoking survivors in cessation through 
pharmacologic and behavioral interventions (Fiore 
et al., 2008). Although effective for the general pop-
ulation, many tobacco cessation interventions have 
not demonstrated the same efficacy for the oncology 
population (de Moor et al., 2008; Nayan et al., 2013). 
In addition, survivors who are aged 40 years and 
younger, are female, are not partnered, and report less 
socioeconomic and psychosocial support may be at 
greater risk for continued smoking after a diagnosis. 
Clinicians should use this information to identify sur-
vivors at risk for continued smoking, provide tailored 
cessation interventions, and follow survivors closely 
to prevent relapse and promote abstinence. 
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